Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Encysive Pharmaceuticals

Request full access

Pulmonary arterial hypertension treatment development and commercialization

Houston, United StatesFounded 1989Health

About Encysive Pharmaceuticals

Encysive Pharmaceuticals Inc., founded as Texas Biotechnology in 1989 and later acquired by Pfizer, was a biopharmaceutical company focused on developing and commercializing small molecule drugs for cardiovascular and inflammatory diseases. The company's main product was Thelin™ (sitaxsentan sodium), an oral, once-daily endothelin A receptor antagonist designed to treat pulmonary arterial hypertension (PAH). Thelin gained marketing approval in the European Union, Canada, and Australia. In the EU, it was indicated for improving exercise capacity in patients with WHO functional class III PAH.

Despite approvals abroad, Encysive faced significant challenges in the United States. The U.S. Food and Drug Administration (FDA) issued multiple approvable letters but did not grant full approval, citing the need for more substantial evidence of effectiveness and recommending an additional Phase III clinical trial. These regulatory hurdles, combined with a strategic review, led to a major restructuring in 2007, which included a 70% reduction of its U.S. workforce and a change in leadership, with George W. Cole replacing Dr. Bruce D. Given as President and CEO.

In February 2008, Pfizer announced its intention to acquire Encysive Pharmaceuticals for approximately $195 million. The acquisition was completed in June 2008, making Encysive a wholly-owned subsidiary of Pfizer. The deal allowed Pfizer to acquire the rights to Thelin and integrate it with its own PAH treatment, Revatio, strengthening its position in the cardio-respiratory market. However, in 2010, Pfizer voluntarily withdrew Thelin from the market due to concerns about liver toxicity. Before the acquisition, Encysive's pipeline also included Argatroban, approved for treating thrombosis, and other compounds in development for conditions like asthma and multiple sclerosis.

Source: Dealroom company data

At a glance

Founded
1989
Headquarters
Houston, United States
Sector
Health

Encysive Pharmaceuticals in the Houston ecosystem

Live from Dealroom

The Encysive Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

1 investor on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later1 investor entered at this stage

  • Hudson Capital Group
Employees 24 total headcount
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Houston HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Encysive Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Encysive Pharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.